Comment on: Conventional immunosuppression: the search for scientific evidence

With a measure of concurrence I read an editorial from Moorfields Eye Hospital [1]. A point was made about the validity of older immunosuppressives in uveitis treatment. Clearly, we cannot shun these drugs as newer and costlier therapies appear for sale. Older drugs have a 40-year record in ophthalmology and vast knowledge exists due to their use in diverse specialities.

Beside older immunosuppressives the newer biologic drugs are costly. We turn to them with avidness in the same way that we turn to a new car. Yet the older car, when justly assessed, is found to be dependable. Older therapies, such as Mycophenolate or Tacrolimus, may be disfavoured because today’s vogue is Adalimumab. In the editorial the musings on commercialism rang true: though effective, old drugs have a shrunken ability to attract money.

Log in or create a free account to read this content

Gain free access to this article, as well as selected content from this journal and more on nature.com

Access through your institution

or

Sign in or create an account

Continue with Google

Continue with ORCiD